📰 Session Title News
Page 4 - Session Title News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Session Title. Real-time updates on events, politics, business and more.
June 1, 2022
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present 17 new abstracts from across its...
May 10, 2022
10.05.2022 - Verve on Track to Begin Dosing HeFH Patients in New Zealand in Mid-2022 in a Phase 1 Clinical Trial with Initial Clinical Data Expected in 2023 Preparing for Submission of United Kingdom and United States Regulatory Filings for VERVE-101 in ...
November 4, 2021
Sixteen new abstracts to be presented, including the first presentation of data from the Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) Phase 2/3 study that supported U.S. FDA
November 4, 2021
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 16 new data abstracts from across its hematology/oncology development program will...
November 4, 2021
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 16 new data abstracts from across its hematology/oncology development program will...
June 4, 2021
Investegate announcements from Diaceutics PLC, Presenting data on COVID impact on cancer at ASCO
May 24, 2021
Panel Session Title: Alzheimer Disease Panel Date and Time: Wednesday May 26th, 11:00 a.m. Eastern time (8:00 a.m. Pacific time) Presented by: Maxim Group LLC | Hosted by: M-Vest Moderated by: Dr. Jason McCarthy About INmune Bio, Inc. INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominan...
April 28, 2021
Share: Longer Term Data from the ALLO-501 Phase 1 ALPHA Study to be Presented Alongside Initial Data from the Phase 1 ALLO-501A ALPHA2 Study Separate Presentation to Include Safety and PK/PD Data on ALLO-647 Used in, Allogenes Proprietary Lymphodepletion Regimen ALLO-501A, Intended for a Potentially Pivotal Phase 2 Trial, Previously Granted FDA Fast Track Designation for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL) Allogene to Host Virtual CD19 Forum to Review ASCO Datasets on May ...
April 28, 2021
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Allogene Therapeutics to Present Data from its Anti-CD19 AlloCAR T™ Therapy Program in ... Allogene Therapeutics, Inc.April 28, 2021 GMT Longer Term Data from the ALLO-501 Phase 1 ALPHA Study to be Presented Alongside Initial Data from the Phase 1 ALLO-501A ALPHA2 Study Separate Presentation to Include Safety and PK/PD Data on ALLO-647 Used in, Allogene’s Proprietary Lymphodepletion Regimen ALLO-5...